药物对比
Tirzepatide vs Insulin Icodec
比较 Tirzepatide（Mounjaro）与每周一次 Insulin Icodec（Awiqli）治疗 2 型糖尿病：双重 GIP/GLP-1 vs 基础胰岛素。A1C、体重减轻、胃肠道影响 vs 低血糖风险。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered for type 2 diabetes patients failing oral therapies who need injectable treatment balancing glycemic control, weight, and injection frequency.
结论
Tirzepatide may be preferable for patients with obesity due to weight loss, while insulin icodec suits those requiring basal insulin support with weekly convenience.
全部药物对比